Growth factors

China Recombinant Human Thrombopoietin (rhTPO) Market Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Pharmaceutical, Growth factors, Cities in China, Thrombopoietin, Shenyang, Recombinant

The "Investigation Report on China's Recombinant Human Thrombopoietin (rhTPO) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Recombinant Human Thrombopoietin (rhTPO) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Recombinant Human Thrombopoietin (rhTPO), developed by Shenyang Sansheng Pharmaceutical Co., Ltd., was approved for marketing in China in 2005 and used to treat thrombocytopenia caused by chemotherapy.
  • According to the market research, the sales value of rhTPO in the Chinese market has increased year by year from 2016 to 2020.
  • 2 Sales of Recombinant Human Thrombopoietin in China, 2016-2020
    2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2016-2020
    3 Analysis of Major Recombinant Human Thrombopoietin Manufacturers in China, 2016-2020
    3.2 Shenyang Sansheng Pharmaceutical Co., Ltd.
    3.2.2 Sales of TPIAO (Shenyang Sansheng Pharmaceutical Co., Ltd.'s Recombinant Human Thrombopoietin) in China
    4 Prices of Recombinant Human Thrombopoietin for Different Manufacturers in China, 2020-2021
    4.1 Shenyang Sansheng Pharmaceutical Co., Ltd. (TPIAO)
    5 Prospect of Chinese Recombinant Human Thrombopoietin drug Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005793/en/

Stimulating blood vessel formation with magnets

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Angiology, Stem cells, Growth factors, Vascular endothelial growth factor, Biotechnology, Endothelium, Stromal cell, Mesenchymal stem cell, Cell therapy, Craniofacial regeneration

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

BioCure Technology Inc. Announces Closing of Financing

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Health care, Branches of biology, Cytokines, Antiviral drugs, Biotechnology, Amgen, Growth factors, Interferon, Biosimilar, Filgrastim, Genentech

The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.

Key Points: 
  • The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.
  • Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer.
  • Biocure, headquartered in Korea, has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021.
  • Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab.

Global Erythropoietin Drugs Market to 2027 by Drug Class, Product, Application, Regional Outlook - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Pharmaceutical, Clinical medicine, Medicine, Branches of biology, Growth factors, Cytokines, Erythropoietin, Chemotherapy, Abbreviated New Drug Application

The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR.
  • The post-abbreviated new drug application (ANDA) is getting approvals and there is a high success rate of erythropoietin drugs in chemotherapy-induced anaemia.
  • Therefore, the impact of the COVID-19 pandemic is likely to have a positive impact on the erythropoietin drug market.

Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Oncology, Branches of biology, Medical specialties, Amgen, Health care, Recombinant proteins, Growth factors, Blood, Neutropenia, Filgrastim, Biosimilar, Cin, Pegfilgrastim

The "Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the CIN, historical and forecasted epidemiology as well as the CIN market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • United States contributes to the major share of the Chemotherapy Induced Neutropenia (CIN) market as compared to other 7MM countries.
  • The current market of Chemotherapy Induced Neutropenia (CIN) is mainly covered by Neulasta, Neupogen, and their biosimilars.

2021 Report on TGF Beta Receptor Type 2 Drugs in Development - Featuring Auxagen, InteRNA Technologies and Velvio Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Health, Pharmaceutical, Branches of biology, Proteins, Biology, TGF beta receptors, Signal transduction, TGF beta receptor 2, Growth factors, Transforming growth factor beta, Transforming growth factor, TGF beta signaling pathway, TGF beta receptor 1

The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.
  • TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene.
  • It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects.

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Amgen, Growth factors, Recombinant proteins, Cytokines, Granulocyte colony-stimulating factor, Pegfilgrastim, Filgrastim, Plinabulin, Neutrophil, Myelocyte

Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).

Key Points: 
  • Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).
  • Immature neutrophil band and promyelocytes and myelocytes are less functional defending against infection and have potentially deleterious immune suppression effects.
  • The Company has submitted New Drug Applications (NDA) for plinabulin in combination with pegfilgrastim as a treatment for the prevention of CIN for review in both the U.S. and China.
  • Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Onco

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Clinical medicine, Medicine, Amgen, Growth factors, Recombinant proteins, Oncology, Granulocyte colony-stimulating factor, Plinabulin, Neutropenia, Pegfilgrastim, Filgrastim

Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.

Key Points: 
  • Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.
  • The poster, titled Chemotherapy Induced Profound Neutropenia (PN) in Patients (pt) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim (Peg) Combination versus (vs) Peg Alone.
  • This is the first study to quantify physical wellbeing (pain and energy levels) of patients receiving plinabulin in combination with pegfilgrastim compared to pegfilgrastim alone.
  • We are very pleased to announce new positive clinical outcome data from the PROTECTIVE-2 Phase 3 program.

Global Anemia in Chronic Kidney Disease Analysis and Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, General Health, Medical specialties, Branches of biology, Clinical medicine, Growth factors, Mineral deficiencies, Anemias, Chronic kidney disease, Organ failure, Iron deficiency, Erythropoietin, Epoetin alfa, Roxadustat

The "Disease Analysis: Anemia in Chronic Kidney Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Anemia in Chronic Kidney Disease" report has been added to ResearchAndMarkets.com's offering.
  • Biosimilars have also taken their toll, particularly in Europe, where biosimilar short-acting ESAs have taken a majority share of usage.
  • Iron is the other major anemia treatment, used for patients with iron deficiency from a potential multitude of causes associated with CKD.
  • Hence, they have the potential to take some market share from ESAs, as well as grow anemia treatment in non-dialysis CKD.